6-MeO-isoDMT
Serotonergic psychoplastogen
From Wikipedia, the free encyclopedia
6-MeO-isoDMT, or 6-OMe-isoDMT, also known as 6-methoxy-N,N-dimethylisotryptamine, is a serotonin 5-HT2A receptor agonist, prospective serotonergic psychedelic, and psychoplastogen of the isotryptamine group.[1][2][3][4][5] It is the isotryptamine analogue of the psychedelic 5-MeO-DMT and is a positional isomer of the non-hallucinogenic psychoplastogen 5-MeO-isoDMT.[2][6][4][5]
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 6-MeO-iso-DMT; 6-Methoxy-isoDMT; 6-OMe-isoDMT; 6-OMe-iso-DMT; 6-Methoxy-iso-DMT; 6-Methoxy-N,N-dimethylisotryptamine |
| Drug class | Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen; Psychoplastogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H18N2O |
| Molar mass | 218.300 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug has been found to substitute for DOM and hence to produce hallucinogen-like effects in animal drug discrimination tests.[1][7][5] However, it has greatly reduced hallucinogenic potential in terms of the head-twitch response, a behavioral proxy of psychedelic effects, compared to 5-MeO-DMT.[2][3][4] It has even been described as "non-hallucinogenic" in at least one publication, although this does not strictly seem to be true.[8] Conversely, 6-MeO-isoDMT has comparable psychoplastogenic potency and effects compared to 5-MeO-DMT.[2][3] These effects are blocked by the serotonin 5-HT2A receptor antagonist ketanserin.[3][4] Certain analogues of 6-MeO-isoDMT, like isoDMT, 5-MeO-isoDMT, and zalsupindole (DLX-001; AAZ-A-154; (R)-5-MeO-α-methyl-isoDMT), produce no head-twitch response at all and hence appear to be fully non-hallucinogenic, similarly to 6-MeO-DMT (the tryptamine analogue of 5-MeO-isoDMT).[1][3][4][5] However, like 6-MeO-isoDMT, they retain potent psychoplastogenic effects.[1][3][4]
6-MeO-isoDMT was first described in the scientific literature by 1984.[5][7] It was subsequently further characterized in 2020.[3][4] Confusingly, the drug has been referred to as "5-MeO-isoDMT" (or rather "5-OMe-isoDMT") in some publications.[6]
